Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice
Zili Luo, Katelin E. Ahlers-Dannen, Mackenzie M. Spicer, Jianqi Yang, Stephanie Alberico, Hanna E. Stevens, Nandakumar S. Narayanan, Rory A. Fisher
Zili Luo, Katelin E. Ahlers-Dannen, Mackenzie M. Spicer, Jianqi Yang, Stephanie Alberico, Hanna E. Stevens, Nandakumar S. Narayanan, Rory A. Fisher
View: Text | PDF
Research Article Neuroscience

Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice

  • Text
  • PDF
Abstract

Parkinson’s disease (PD) is primarily a nonfamilial, age-related disorder caused by α-synuclein accumulation and the progressive loss of dopamine neurons in the substantia nigra pars compacta (SNc). GPCR-cAMP signaling has been linked to a reduction in human PD incidence and α-synuclein expression. Neuronal cAMP levels are controlled by GPCRs coupled to Gs or Gi/o, which increase or decrease cAMP, respectively. Regulator of G protein signaling 6 (RGS6) powerfully inhibits Gi/o signaling. Therefore, we hypothesized that RGS6 suppresses D2 autoreceptor-Gi/o signaling in SNc dopamine neurons promoting neuronal survival and reducing α-synuclein expression. Here, we provide potentially novel evidence that RGS6 critically suppresses late-age-onset SNc dopamine neuron loss and α-synuclein accumulation. RGS6 is restrictively expressed in human SNc dopamine neurons and, despite their loss in PD, all surviving neurons express RGS6. RGS6–/– mice exhibit hyperactive D2 autoreceptors with reduced cAMP signaling in SNc dopamine neurons. Importantly, RGS6–/– mice recapitulate key sporadic PD hallmarks, including SNc dopamine neuron loss, reduced nigrostriatal dopamine, motor deficits, and α-synuclein accumulation. To our knowledge, Rgs6 is the only gene whose loss phenocopies these features of human PD. Therefore, RGS6 is a key regulator of D2R-Gi/o signaling in SNc dopamine neurons, protecting against PD neurodegeneration and α-synuclein accumulation.

Authors

Zili Luo, Katelin E. Ahlers-Dannen, Mackenzie M. Spicer, Jianqi Yang, Stephanie Alberico, Hanna E. Stevens, Nandakumar S. Narayanan, Rory A. Fisher

×

Figure 7

The proposed role of RGS6 in the regulation of presynaptic D2 receptor signaling in SNc DA neurons.

Options: View larger image (or click on image) Download as PowerPoint
The proposed role of RGS6 in the regulation of presynaptic D2 receptor s...
Gi/o-coupled D2Rs expressed presynaptically on DA neurons (Supplemental Figure 1) act as autoreceptors inhibiting DA synthesis and vesicular DA release as well as upregulating DAT though multiple mechanisms (37–40, 79). Left: Our data indicated that, by serving as a gatekeeper for D2R-Gi/o signaling in SNc DA neurons, RGS6 ensures normal DA homeostasis and neurotransmission as well as suppresses aberrant accumulation of α-synuclein. By inhibiting D2R-Gi/o signaling, RGS6 promotes cAMP-PKA signaling, which increases DA synthesis (by TH phosphorylation) and suppresses α-synuclein expression similarly to cAMP-elevating β-agonists. RGS6 also promotes normal DA packaging and release by inhibiting D2R-Gi/o–mediated inhibition of VMAT2 as well as upregulation/activation of DAT. Right: Loss of RGS6 disinhibits D2R-Gi/o signaling, which reduces cAMP and its effects on DA synthesis as well as α-synuclein accumulation, while simultaneously leading to accumulation of cytotoxic DA by D2R-Gi/o-mediated inhibition of VMAT2 and upregulation of DAT.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts